Goldman Sachs Group Inc Fate Therapeutics Inc Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,823,403 shares of FATE stock, worth $4.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,823,403
Previous 2,348,554 20.22%
Holding current value
$4.69 Million
Previous $7.7 Million 28.27%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.12 - $5.57 $1.48 Million - $2.64 Million
474,849 Added 20.22%
2,823,403 $9.88 Million
Q2 2024

Aug 13, 2024
BUY
$3.26 - $7.08 $1.1 Million - $2.38 Million
336,296 Added 16.71%
2,348,554 $7.7 Million
Q1 2024

May 15, 2024
BUY
$3.54 - $8.35 $5.03 Million - $11.9 Million
1,421,265 Added 240.49%
2,012,258 $14.8 Million
Q4 2023

Feb 13, 2024
BUY
$1.65 - $3.94 $159,269 - $380,316
96,527 Added 19.52%
590,993 $2.21 Million
Q3 2023

May 14, 2024
SELL
$2.02 - $5.04 $194,984 - $486,496
-96,527 Reduced 16.33%
494,466 $1.05 Million
Q3 2023

Nov 14, 2023
SELL
$2.02 - $5.04 $1.19 Million - $2.98 Million
-590,367 Reduced 54.42%
494,466 $1.05 Million
Q2 2023

May 14, 2024
SELL
$4.76 - $6.59 $1.16 Million - $1.61 Million
-243,828 Reduced 18.35%
1,084,833 $5.16 Million
Q2 2023

Aug 14, 2023
SELL
$4.76 - $6.59 $1.16 Million - $1.61 Million
-243,828 Reduced 18.35%
1,084,833 $5.16 Million
Q1 2023

May 14, 2024
BUY
$4.24 - $11.12 $2.2 Million - $5.77 Million
518,625 Added 64.02%
1,328,661 $7.57 Million
Q1 2023

May 11, 2023
BUY
$4.24 - $11.12 $2.2 Million - $5.77 Million
518,625 Added 64.02%
1,328,661 $7.57 Million
Q4 2022

May 14, 2024
SELL
$9.86 - $23.83 $2.28 Million - $5.52 Million
-231,691 Reduced 22.24%
810,036 $8.17 Million
Q4 2022

Feb 13, 2023
SELL
$9.86 - $23.83 $2.28 Million - $5.52 Million
-231,691 Reduced 22.24%
810,036 $8.17 Million
Q3 2022

May 14, 2024
SELL
$21.04 - $36.06 $903,520 - $1.55 Million
-42,943 Reduced 3.96%
1,041,727 $23.3 Million
Q3 2022

Nov 10, 2022
SELL
$21.04 - $36.06 $903,520 - $1.55 Million
-42,943 Reduced 3.96%
1,041,727 $23.3 Million
Q2 2022

May 14, 2024
BUY
$17.78 - $42.39 $8.78 Million - $20.9 Million
493,677 Added 83.53%
1,084,670 $26.9 Million
Q2 2022

Aug 15, 2022
BUY
$17.78 - $42.39 $15.3 Million - $36.4 Million
858,193 Added 378.93%
1,084,670 $26.9 Million
Q1 2022

May 16, 2022
SELL
$29.67 - $60.28 $5.36 Million - $10.9 Million
-180,694 Reduced 44.38%
226,477 $8.78 Million
Q4 2021

Feb 14, 2022
SELL
$47.84 - $64.34 $7.83 Million - $10.5 Million
-163,752 Reduced 28.68%
407,171 $23.8 Million
Q3 2021

Nov 10, 2021
BUY
$59.27 - $95.73 $33.8 Million - $54.7 Million
570,923 New
570,923 $33.8 Million

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $161M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email